Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
- Author:
Sergey VTORUSHIN
1
;
Anastasia DULESOVA
2
;
Nadezhda KRAKHMAL
3
Author Information
- Publication Type:Review
- Keywords: Androgen receptor (AR); Luminal androgen receptor (LAR) subtype; Prognosis; Triple-negative breast cancer (TNBC)
- MeSH: Carcinoma; Humans; Receptors, Androgen/genetics*; Triple Negative Breast Neoplasms/pathology*
- From: Journal of Zhejiang University. Science. B 2022;23(8):617-624
- CountryChina
- Language:English
- Abstract: According to the classification presented by Lehmann BD (2016), triple-negative breast cancer (TNBC) is a heterogeneous group of malignant tumors with four specific subtypes: basal-like (subtype 1 and subtype 2), mesenchymal, and luminal androgen receptor (LAR) subtypes. The basal-like subtypes of carcinomas predominate in this group, accounting for up to 80% of all cases. Despite the significantly lower proportions of mesenchymal and LAR variants in the group of breast carcinomas with a TNBC profile, such tumors are characterized by aggressive biological behavior. To this end, the LAR subtype is of particular interest, since the literature on such tumors presents different and even contradictory data concerning the disease course and prognosis. This review is devoted to the analysis of the relevant literature, reflecting the main results of studies on the molecular properties and clinical features of the disease course of LAR-type TNBC carcinomas.
